Company intelligence / Profile preview

HTL-Strefa

Holmdel, New Jersey, United Statesmtdglobal.com ↗

Ownership: Private
Employees: ~188
Development stage: Commercial

Overview

HTL-Strefa's products are widely used globally for diabetes care and diagnostic testing. The company leads in safety lancet technology and pen needle innovation. Its Droplet brand has become the fastest-growing pen needle brand in North America. The company’s DropSafe Sicura passive safety needle addresses needlestick injury prevention with FDA clearance.

Therapeutic areas: OtherEndocrinologyInfectious Diseases
Modalities: Device (pen needles, safety pen needles, lancets)Non-pharmacological therapy (blood sampling and drug delivery devices)
Industry: Consumable Medical Devices

Beyond the preview

Go deeper on HTL-Strefa.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HTL-Strefa.

Explore the full profile